4-(4-肼基苯基) -1,2,4-三唑盐酸盐 | 154594-16-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(4-肼基苯基) -1,2,4-三唑盐酸盐
• 中文别名: 4-(4-肼基苯基)-1,2,4-三唑盐酸盐；4-(4-肼基苯基)-4H-1,2,4-三氮唑；4-(4-肼基苯基)-(9ci)-4H-1,2,4-噻唑；1-(4-肼基苯基)-1H-1,2,4-三氮唑
• 英文名称: 4-(1,2,4-triazol-4-yl)phenylhydrazine
• 英文别名: 4-(4-hydrazinylphenyl)-4H-1,2,4-triazole；[4-(1,2,4-triazol-4-yl)phenyl]hydrazine
• CAS: 154594-16-8
• 化学式: C₈H₉N₅
• mdl: MFCD02663159
• 分子量: 175.193
• InChiKey: LDKIYTFDNJHIGI-UHFFFAOYSA-N

物化性质

• 沸点：
  410.1±47.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  68.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-(4-肼基苯基) -1,2,4-三唑盐酸盐 在 盐酸 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 异丙醇 、 甲苯 、 乙腈 为溶剂， 生成 4-Benzyl-3-methyl-1-(3-[5-(1,2,4-triazol-4-yl)-1H-indol-3-yl]propyl)-1,2,5,6-tetrahydropyridine Hydrogen Oxalate
  参考文献：
  名称：

  Substituted tetrahydropyridine derivatives acting on 5-HT receptors

  摘要：

  具有化学式I的化合物，或其盐或前药：##STR1## 是5-HT.sub.1D.alpha.受体的选择性激动剂，可用于治疗偏头痛及相关疾病。

  公开号：

  US06054469A1
• 作为产物：
  描述：

  对硝基乙酰苯胺 在 palladium on activated charcoal 盐酸 、 氢气 、 对甲苯磺酸 、 tin(ll) chloride 、 sodium nitrite 作用下， 以 乙醇 、 乙酸乙酯 、 甲苯 为溶剂， 反应 2.0h， 生成 4-(4-肼基苯基) -1,2,4-三唑盐酸盐
  参考文献：
  名称：

  The chemical evolution of N,N-dimethyl-2-[5-(1,2,4-triazol-4-yl)-1H-indol-3-yl]ethylamine (L-741,604) and analogues: Potent and selective agonists for 5-HT1D receptors

  摘要：

  Optimisation of a series of 5-(heterocyclyl)tryptamines led to the identification of the symmetrically substituted, N-4 linked 1,2,4-triazole as the best indole C-5 substituent for 5-HT1D receptor affinity and selectivity. The triazole (8) is the most potent and selective, orally bioavailable, 5-HT1D receptor agonist identified to date, showing an order of magnitude greater potency than the clinical compound sumatriptan with improved subtype selectivity. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00324-1

文献信息

• Diazabicyclo-octane derivatives as 5-HT receptor ligands
  申请人：Merck Sharp & Dohme Ltd.

  公开号：US06150391A1

  公开（公告）日：2000-11-21

  Compounds having formula I, or pharmaceutically acceptable salts or prodrugs thereof: ##STR1## are selective agonists of the 5-HT.sub.1D.alpha. receptor and are useful in the treatment of migraine and associated conditions.

  具有化学式I的化合物，或其药学上可接受的盐或前药：##STR1## 是5-HT.sub.1D.alpha.受体的选择性激动剂，对治疗偏头痛及相关症状有用。
• Substituted indolylpropyl-piperazine derivatives as 5-HT.sub.1D .alpha.
  申请人：Merck Sharp & Dohme Limited

  公开号：US05981529A1

  公开（公告）日：1999-11-09

  A class of 1-[3-(1H-indol-3-yl)propyl]-4-(2-phenylethyl)piperazine derivatives, substituted at the 5-position of the indole nucleus by a five-membered heteroaromatic moiety, on one or other of the ethylene carbon atoms of the phenethyl moiety by halogen, trifluoromethyl, alkyl, hydroxyalkyl or alkoxyalkyl, and optionally on the phenyl ring of the phenethyl moiety by halogen, trifluoromethyl, alkoxy or an oxazolidinone group and optionally by one or two further substituents, are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D .alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D .alpha. receptor subtype relative to the 5-HT.sub.1D .beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.

  一类1-[3-(1H-吲哚-3-基)丙基]-4-(2-苯乙基)哌嗪衍生物，通过在吲哚核的5位被一个五元杂环芳基取代，在苯乙基的乙烯碳原子上通过卤素、三氟甲基、烷基、羟基烷基或烷氧基取代，以及在苯乙基的苯环上通过卤素、三氟甲基、烷氧基或氧杂环丙酮基，并可选择性地通过一个或两个进一步的取代基，它们是5-HT.sub.1-样受体的选择性激动剂，是人类5-HT.sub.1D .alpha.受体亚型的有效激动剂，同时相对于5-HT.sub.1D .beta.亚型具有至少10倍的选择性亲和力；因此，在治疗和/或预防临床病症，特别是偏头痛及相关疾病方面，对于需要5-HT.sub.1D受体亚型选择性激动剂的情况，它们比非亚型选择性的5-HT.sub.1D受体激动剂引起的副作用更少，尤其是不良心血管事件。
• Piperazine, piperidine and tetrahydropyridine derivative of
  申请人：Merck Sharp & Dohme Ltd.

  公开号：US05807857A1

  公开（公告）日：1998-09-15

  Compounds of formula (I), or a salt or prodrug thereof, wherein Z represents an optionally substituted five-membered heteroaromatic ring selected from furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole; E represents a chemical bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms; Q represents a straight or branched alkylene chain containing from 1 to 6 carbon atoms, optionally substituted in any position by a hydroxy group; T represents nitrogen or CH; U represents nitrogen or C--R.sup.2 ; V represents oxygen, sulphur or N--R.sup.3 ; --F--G-- represents --CH2--N--, --CH2--CH-- or --CH.dbd.C--; R.sup.1 represents C.sub.3-6 alkenyl, C.sub.3-6 alkynyl, aryl(C.sub.1-6)alkyl or heteroaryl(C.sub.1-6)alkyl, any of which groups may be optionally substituted; and R.sup.2 and R.sup.3 independently represent hydrogen or C.sub.1-6 alkyl are selective agonists of 5-HT1D receptors, being potent agonists of the human 5-HT1Dalpha receptor subtype, while possessing at least a 10-fold selective affinity for the 5-HT1Dalpha receptor subtype, relative to the 5-HT1Dbeta subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, while eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.

  式(I)的化合物，或其盐或前药，其中Z代表从呋喃、噻吩、吡咯、噁唑、噻唑、异噁唑、异噻唑、咪唑、吡唑、噁二唑、噻二唑、三唑和四唑中选择的可选择性取代的五元杂芳环；E代表化学键或含有1至4个碳原子的直链或支链烷基链；Q代表含有1至6个碳原子的直链或支链烷基链，在任何位置可选择性地被羟基取代；T代表氮或CH；U代表氮或C--R.sup.2；V代表氧、硫或N--R.sup.3；--F--G--代表--CH2--N--，--CH2--CH--或--CH.dbd.C--；R.sup.1代表C.sub.3-6烯基、C.sub.3-6炔基、芳基(C.sub.1-6)烷基或杂芳基(C.sub.1-6)烷基，其中任何一个基团可选择性地被取代；而R.sup.2和R.sup.3独立地代表氢或C.sub.1-6烷基，是5-HT1D受体的选择性激动剂，是人类5-HT1Dα受体亚型的有效激动剂，同时相对于5-HT1Dbeta亚型，具有至少10倍的选择性亲和力；因此，在治疗和/或预防临床病症方面特别是偏头痛及相关疾病方面，对于需要5-HT1D受体亚型选择性激动剂的情况，比非亚型选择性5-HT1D受体激动剂引起的副作用更少，尤其是不良心血管事件。
• 3-[3-(Piperidin-1-yl)propyl]indoles as Highly Selective h5-HT_1D Receptor Agonists
  作者：Michael G. N. Russell、Victor G. Matassa、Roy R. Pengilley、Monique B. van Niel、Bindi Sohal、Alan P. Watt、Laure Hitzel、Margaret S. Beer、Josephine A. Stanton、Howard B. Broughton、José L. Castro

  DOI：10.1021/jm9910021

  日期：1999.12.2

  5-HT(1D/1B) receptor agonists are now entering the marketplace as treatments for migraine. This paper describes the development of selective h5-HT(1D) receptor agonists as potential antimigraine agents which may produce fewer side effects. A series of 3-[3-(piperidin-1-yl)propyl]indoles has been synthesized which has led to the identification of 80 (L-772,405), a high-affinity h5-HT(1D) receptor full agonist

  几种5-HT（1D / 1B）受体激动剂目前正作为偏头痛的治疗方法进入市场。本文介绍了选择性的h5-HT（1D）受体激动剂作为潜在的偏头痛药物的发展，它可能产生较少的副作用。合成了一系列3- [3-（哌啶-1-基）丙基]吲哚，该化合物导致鉴定出80（L-772,405），这是一种具有170的高亲和力h5-HT（1D）受体全激动剂对h5-HT（1D）受体的选择性是h5-HT（1B）受体的两倍。L-772,405在一系列其他5-羟色胺和非5-羟色胺受体上也表现出非常好的选择性，并且在大鼠皮下给药后具有出色的生物利用度。因此，它构成了描述偏头痛中h5-HT（1D）受体作用的有价值的工具。
• Fluorination of 3-(3-(Piperidin-1-yl)propyl)indoles and 3-(3-(Piperazin-1-yl)propyl)indoles Gives Selective Human 5-HT_1D Receptor Ligands with Improved Pharmacokinetic Profiles
  作者：Monique B. van Niel、Ian Collins、Margaret S. Beer、Howard B. Broughton、Susan K. F. Cheng、Simon C. Goodacre、Anne Heald、Karen L. Locker、Angus M. MacLeod、Denise Morrison、Christopher R. Moyes、Desmond O'Connor、Andrew Pike、Michael Rowley、Michael G. N. Russell、Balbinder Sohal、Josephine A. Stanton、Steven Thomas、Hugh Verrier、Alan P. Watt、José L. Castro

  DOI：10.1021/jm981133m

  日期：1999.6.1

  It has previously been reported that a 3-(3-(piperazin-1-yl)propyl)indole series of 5-HT1D receptor ligands have pharmacokinetic advantages over the corresponding 3-(3-(piperidin-1-yl)propyl)indole series and that the reduced pKa of the piperazines compared to the piperidines may be one possible explanation for these differences. To investigate this proposal we have developed versatile synthetic strategies

  以前已经报道过，3-（3-（哌嗪-1-基）丙基）吲哚系列的5-HT1D受体配体比相应的3-（3-（哌啶-1-基）丙基）吲哚具有药代动力学优势。与哌啶相比，哌嗪的pKa降低可能是这些差异的一种可能解释。为了研究该提议，我们开发了将氟掺入这些配体中的通用合成策略，生产出一系列新的4-氟哌啶，3-氟-4-氨基哌啶，以及哌嗪和哌啶衍生物，其丙基连接基中带有一个或两个氟。 。鉴定了对5-HT1D受体保持高亲和力和选择性并在体外显示激动剂功效的配体。发现掺入氟可显着降低化合物的pKa，